Olatorepatide is a peptide analogue under investigation for the treatment of overweight and obesity. Trial records describe its study in adults with overweight or obesity, including those with the inflammatory skin condition hidradenitis suppurativa, suggesting involvement in metabolic and potentially inflammatory pathways.
Investigational. Multiple Phase 2 trials ongoing or planned across overweight/obesity and hidradenitis suppurativa indications; not FDA-approved.
Last reviewed October 13, 2026
The calculator takes vial mass, BAC water volume and your target dose, and returns the exact draw on a U-40, U-50 or U-100 insulin syringe. It does the arithmetic; it does not suggest what the dose should be.
Open the reconstitution calculator →